Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a dose-ranging study of CBL-514 for abdominal subcutaneous fat reduction
ACTRN12619001580167Phase 2Recruiting
- Sponsor
- Caliway Biopharmaceuticals
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CBL-514 in Localized abdominal subcutaneous fat excess (3 arms), sponsored by Caliway Biopharmaceuticals. Primary endpoint: Change from baseline in waist circumference. Started Feb 2020; status: recruiting.
02
Drugs
CBL-514
03
Conditions
Localized abdominal subcutaneous fat excess
Beyond the preview
Go deeper on ACTRN12619001580167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001580167.